Compare CLNE & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLNE | KMDA |
|---|---|---|
| Founded | 2001 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.9M | 458.6M |
| IPO Year | 2006 | 2013 |
| Metric | CLNE | KMDA |
|---|---|---|
| Price | $2.38 | $8.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $3.49 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.2M | 65.5K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $341,599,000.00 | N/A |
| Revenue This Year | $5.99 | $14.79 |
| Revenue Next Year | $17.00 | $11.38 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.30 | $5.54 |
| 52 Week High | $3.11 | $9.35 |
| Indicator | CLNE | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 56.02 |
| Support Level | $2.36 | $6.69 |
| Resistance Level | $2.55 | $9.35 |
| Average True Range (ATR) | 0.11 | 0.27 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 39.81 | 60.00 |
Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas and liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The firm operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. It also builds, operates, and maintains natural gas fueling stations for customers.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.